Characteristics of new malignancies
| Characteristic . | SPM . |
|---|---|
| No. of patients | 175 |
| No. of centers | 66 |
| Number of new malignancies--no. (%) | |
| 1 | 165 (94) |
| 2 | 10 (6) |
| Classification of new malignancies--no. (%) | |
| Myeloid∗ | 36 (21) |
| Lymphoid† | 3 (2) |
| SHM, not otherwise specified‡ | 24 (14) |
| Solid tumor | 112 (64) |
| Time from HCT to new malignancy--median (min-max) | 33 (2-96) |
| New malignancy: AML/MDS--no. (%) | |
| No | 139 (79) |
| Yes | 36 (21) |
| Time from HSCT to SHM--median (min-max) | 35 (3-93) |
| Time from HSCT to solid tumor--median (min-max) | 33 (2-96) |
| Characteristic . | SPM . |
|---|---|
| No. of patients | 175 |
| No. of centers | 66 |
| Number of new malignancies--no. (%) | |
| 1 | 165 (94) |
| 2 | 10 (6) |
| Classification of new malignancies--no. (%) | |
| Myeloid∗ | 36 (21) |
| Lymphoid† | 3 (2) |
| SHM, not otherwise specified‡ | 24 (14) |
| Solid tumor | 112 (64) |
| Time from HCT to new malignancy--median (min-max) | 33 (2-96) |
| New malignancy: AML/MDS--no. (%) | |
| No | 139 (79) |
| Yes | 36 (21) |
| Time from HSCT to SHM--median (min-max) | 35 (3-93) |
| Time from HSCT to solid tumor--median (min-max) | 33 (2-96) |
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
Myeloid diagnoses: AML, n = 9; MDS, n = 14: AML+MDS, n = 2; AML+MDS/MPN, n = 2; MDS/MPN, n = 9.
Lymphoid diagnoses: ALL, n = 1; Hodgkin’s lymphoma, n = 1; lymphoproliferative disorder, n = 1.
SHM, not otherwise specified diagnoses: other leukemia, n = 21; other leukemia+breast cancer, n = 1; other leukemia+melanoma, n = 1; other leukemia+thyroid cancer, n = 1.